Site-specific conjugation onto capsid proteins enables altering of extracellular capsid sequestration, by blocking the binding of the AAV capsid to extracellular motifs.
Ligands are rationally designed to improve cell and tissue targeting, based on defined ligand-receptor interactions.
Site-specific conjugation of capsid proteins leads to improvement of intracellular AAV capsid trafficking and payload delivery to the nucleus.
Ligand conjugation reduces coAAV exposure to immune reaction and neutralizing antibodies.
Inherited retinal dystrophies are rare ophthalmic pathologies that can be divided into two groups:
Retinitis pigmentosa is the most common form of inherited retinal dystrophy representing 50% of all retinal dystrophies.
While multiple genes are implicated in each of these groups, within each patient or family, only one causative gene is involved.
PDE6b RP is an inherited retinal dystrophy that leads to blindness by midlife and is characterized by the progressive loss of photoreceptors, with or without the loss of retinal pigment epithelium cells.
It is caused by mutation of the PDE6b gene resulting in dysfunctional Rod PDE6, an enzyme found in rod outer segments that plays a key role in the phototransduction cascade in rods (the process by which light is converted into electrical signals). Dysfunction of the PDE6 protein, and in particular its PDE6ß subunit, ultimately leads to death of rod photoreceptor cells, then cone photoreceptor cells, leading to blindness.
Mutation of PDE6b is one of the most prevalent human mutations within autosomal recessive RP and accounts for 2-4% of RP cases.
There are currently no approved treatments for PDE6b RP.
CTx-PDE6b is an AAV based gene therapy designed to deliver a full-length non-mutated copy of the functional human PDE6b gene into the subretinal space, where it rapidly induces robust transgene expression and synthesis of functional PDE6b proteins in photoreceptive rods and cones. By effectively providing these cells with a functional protein, CTx-PDE6b may significantly delay or halt retinal degeneration in PDE6ß-deficient patients.
CTx-PDE6b is currently in Phase I/II clinical trials.
A description of the protocol can be found on clinicaltrials.gov
Parkinson’s disease is a severe and progressive neurodegenerative disorder that affects more than seven million people worldwide.
Population-based genetic studies have recently identified several causative and risk genes for Parkinson’s disease. Many of these genes are involved in the normal functioning of lysosomes, a cell organelle containing enzymes responsible for degrading biomolecules.
The GBA1 gene encodes the lysosomal enzyme beta-glucocerebrosidase (GCase), which is needed for the disposal and recycling of glycolipids — a type of cellular lipid component that is known to accumulate with aging. Mutations in the GBA1 gene lead to a deficiency of GCase and are associated with earlier onset of Parkinson’s disease, with more severe symptoms, and increased likelihood of progression to dementia.
There are currently no approved therapies that modify the course of Parkinson’s disease or the underlying pathological process.
Gaucher disease is a lysosomal storage disorder caused by mutations in both copies of the GBA1 gene, which can have a wide range of effects on organs throughout the body. Gaucher disease has three subtypes (Type 1, 2 and 3), which vary by the presence or absence of neurological symptoms, severity of symptoms, age of onset and age at death.
Type 2 and Type 3 Gaucher diseases are the most severe forms and are present in either childhood or adulthood. They involve neurological symptoms and, in infants or toddlers (Type 2), cause rapid and irreversible brain damage beginning in the first six months of life.
Enzyme replacement therapies (ERTs) are approved for the treatment of Type 1 Gaucher disease but are only effective in treating the peripheral symptoms of disease, since they cannot cross the blood brain barrier. There are currently no approved therapies for the neurologic manifestations of Gaucher disease.
Our gene therapy product candidate, CTx-GBA1, utilizes a coAAV vector to deliver a gene sequence encoding functional GCase enzyme. CTx-GBA1 has been optimized for improved transduction and distribution of the GBA1 gene in the key structure of the brain involved in Parkinson’s and neuronopathic Gaucher diseases.
June, 9 – 2022
May, 4 – 2022
April, 27 – 2022
April, 13 – 2022
November, 15 – 2021
October, 12 – 2021
September, 23 – 2021
September, 16 – 2021
July, 21 – 2021
May, 13 — 2022
The Associate Director Discovery Science, reporting to the Head of Discovery Science, will participate in the development of the AAV capsid improvement strategy and will be responsible for its operational execution to deliver improved AAV vectors, including chemically-conjugated AAVs (coAAVs), for Coave Therapeutics’ indications of interest in the neurologic and ophthalmologic spaces. This position will be based at Coave Therapeutics’ Lab in the Institut du Cerveau et de la Moelle (ICM) in Paris, France. Set in a dynamic environment, it will include the management and mentoring of a team of Research Engineers and Scientists.
We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare ocular and CNS diseases and beyond.
We are committed to building a vibrant team combining deep expertise in AAV vector engineering and genetic construct design, innovative and advanced therapeutic product development, and manufacturing.
We are looking for more talented individuals to join our team.
63bis avenue Ledru Rolin
75012 Paris – France
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIÈRE – ICM
47 bd de l’Hôpital